EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Low levels of CD3 + and CD8 + T cells in peripheral blood can predict poor efficacy of first-line chemotherapy in patients with angioimmunoblastic T cell lymphoma

Yanfei Liu, Weiwei Song, Yuqin Song, Jun Zhu, Yan Xie

Annals of Hematology · 2025

DOI: 10.1007/s00277-025-06314-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, 2025. Verfasst von Yanfei Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Inst…. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, CD3 Complex, Immunoblastic Lymphadenopathy, Lymphoma, T-Cell. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The Capital's Funds for Health Improvement and Research, National Key Research and Development Program of Chin, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To investigate the prognostic significance of lymphocyte subsets in newly diagnosed angioimmunoblastic T-cell lymphoma (AITL) patients and track the dynamic changes in these subsets during treatment. We retrospectively analyzed the medical records in 56 patients with AITL. Lymphocyte subsets were assessed by flow cytometry at diagnosis. Receiver operating characteristic curves were employed to establish optimal cut-off values for lymphocyte subset assessment. Univariate and multivariate analyses were used to evaluate overall survival (OS) and progression-free survival (PFS). The first-line treatment demonstrated an overall response rate (ORR) of 71.4%. Optimal cut-off values for ORR were determined for CD3 + T cell percentage (61.9%) and CD8 + T cell percentage (28.4%), with corresponding AUC of 0.756 [95% CI (0.611-0.902), p = 0.003] and 0.745 [95% CI (0.596-0.894), p = 0.004]. The ORR for the Low CD3+/CD8 + Group (CD3 + T < 61.9% and CD8 + T < 28.4%) and High CD3+/CD8 + Group (CD3 + T ≥ 61.9% or CD8 + T ≥ 28.4%) was 25.0% and 84.1%, respectively (p < 0.001). With a median follow-up time of 37.4 months, the median PFS were 5.6 and 16.0 months for the both groups. After two cycles of chemotherapy, a significant elevation in the percentage of CD3 + T cells was observed comparing to pre-treatment. Three months post-treatment, the CD4/CD8 ratio reduced significantly, indicating a rebalancing of T cell populations. Reduced levels of CD3 + and CD8 + T lymphocyte may indicate inferior chemotherapy efficacy and poorer PFS in AITL. Monitoring the baseline lymphocyte subsets and their dynamic changes can assist in clinical treatment decision - making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesCD3 ComplexImmunoblastic LymphadenopathyLymphoma, T-CellAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAdultAged, 80 and overLymphocyte CountTreatment OutcomePrognosis

Stichwörter der Autor:innen

Angioimmunoblastic T-cell lymphomaCD8 + T cellsLymphocyte subsetsPrognosisResponse rate

Substanzen

CD3 Complex

Autor:innen und Institutionen

  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China. xielao…

Förderung

  • The Capital's Funds for Health Improvement and Research
  • National Key Research and Development Program of Chin
  • National Natural Science Foundation of China
  • Beijing Natural Science Foundation
  • Cultivation plan in Haidian District
  • Beijing Hospital Authority Cultivation plan
  • Beijing Research Ward Excellence Program

Zitieren

APA

Liu, Y., Song, W., Song, Y., Zhu, J., & Xie, Y. (2025). Low levels of CD3 + and CD8 + T cells in peripheral blood can predict poor efficacy of first-line chemotherapy in patients with angioimmunoblastic T cell lymphoma. Annals of Hematology. https://doi.org/10.1007/s00277-025-06314-0

Vancouver

Liu Y, Song W, Song Y, Zhu J, Xie Y. Low levels of CD3 + and CD8 + T cells in peripheral blood can predict poor efficacy of first-line chemotherapy in patients with angioimmunoblastic T cell lymphoma. Annals of Hematology. 2025. doi:10.1007/s00277-025-06314-0

BibTeX
@article{Liu2025,
  author = {Liu, Yanfei and Song, Weiwei and Song, Yuqin and Zhu, Jun and Xie, Yan},
  title = {Low levels of CD3 + and CD8 + T cells in peripheral blood can predict poor efficacy of first-line chemotherapy in patients with angioimmunoblastic T cell lymphoma},
  journal = {Annals of Hematology},
  year = {2025},
  doi = {10.1007/s00277-025-06314-0}
}
Kostenlos starten →